An orthogonally activatable CRISPR-Cas13d nanoprodrug to reverse chemoresistance for enhanced chemo-photodynamic therapy

Orthogonal therapy that combines CRISPR-based gene editing and prodrug-based chemotherapy is a promising approach to combat multidrug-resistant cancer. However, its potency to precisely regulate different therapeutic modalities in vivo is limited due to the lack of an integrated platform with high s...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zheng, Feng, Zhiyuan, Chen, Mohan, Zhan, Jiayin, Wu, Rong, Shi, Yang, Xue, Yunsheng, Liu, Ran, Zhu, Jun-Jie, Zhang, Jingjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2023
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094006/
https://www.ncbi.nlm.nih.gov/pubmed/37063792
http://dx.doi.org/10.1039/d3sc00020f

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094006/
https://www.ncbi.nlm.nih.gov/pubmed/37063792
http://dx.doi.org/10.1039/d3sc00020f

Ejemplares similares